INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPRNewsWire · 2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERGlobeNewsWire · 4 days ago
Omeros (NASDAQ:OMER) Shares Gap Down – Here’s WhyDefense World · Oct 18, 2026
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program EndsBenzinga · Oct 16, 2026
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMABusiness Wire · Oct 16, 2026
Omeros (NASDAQ:OMER) Hits New 1-Year High – Should You Buy?Defense World · Sep 24, 2026Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.27 | $0.15 | Beat |
| May 13, 2026 | -$0.40 | -$0.24 | Beat |
| Mar 31, 2026 | -$0.55 | $3.14 | Beat |
| Nov 13, 2025 | -$0.58 | -$0.47 | Beat |
| Aug 14, 2025 | -$0.55 | -$0.43 | Beat |
| May 15, 2025 | -$0.57 | -$0.58 | Miss |